-
O’Mathuna D. Rhodiola Rosea (Roseroot) for Generalized Anxiety, Depression, and Fatigue. Alter Med Alert. 2008:11;73-75.
-
Keifer, D. The Mushroom Agaricus Blazei and Chronic Hepatitis B. Alter Med Alert. 2008:11;76-78.
-
O’Mathuna D. Climacteric Syndrome during Peri-menopause: Pycnogenol. (originally published in the March 2008 issue of Alternative Therapies in Women’s Health) Alter Med Alert. 2008:11;73-75.
-
Greenfield, RH. Sweet Sleep – Honey and Nighttime Cough. Alter Med Alert. 2008:11;81.
Greenfield, RH. In Vino Veritas – Resveratrol and Aging. Alter Med Alert. 2008:11;82.
Greenfield, RH. Get Moving – Exercise and Breast Cancer Risk. Alter Med Alert. 2008:11;83.
-
-
-
Gary Burbach is president, CEO and a board member of Thoratec (Pleasanton, California), the leading developer of ventricular assist devices used for those with severe heart failure.
-
CHICAGO Developments (and controversies) concerning drug-eluting stents (DES) first and second-generation devices and those to come weren't the only newsworthy topics at this year's scientific session of the American College of Cardiology (Washington).
-
In light of recent news that blood substitutes have led to a 30% increase in the risk of death and a nearly threefold chance of having a heart attack, Synthetic Blood International (SBI; Costa Mesa, California) has attempted to distance itself from the "blood substitute" sector.
-
SILVER SPRING, Maryland The cost of developing a drug-eluting stent (DES) has been pegged as somewhere north of $100 million, but that number has not deterred several device makers from wading into this end of the cardiovascular device pool.
